Clinical Trials Directory

Trials / Terminated

TerminatedNCT00446589

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Papageorgiou General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hemodialysis patients with low bone density (total hip T-score \<-2.5) will be assigned to receive teriparatide (those with histologic confirmation of adynamic bone disease) or ibandronate (subjects with increased osteoclast number on bone biopsy). Follow-up period: one year. A second bone biopsy at the end of the study.

Conditions

Interventions

TypeNameDescription
DRUGibandronateiv 1mg ibandronate monthly for one year
DRUGteriparatidesc injection using a pen like device during every hemodialysis session (thrice a week)

Timeline

Start date
2006-07-01
First posted
2007-03-13
Last updated
2014-10-29

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT00446589. Inclusion in this directory is not an endorsement.

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis (NCT00446589) · Clinical Trials Directory